Histological Evaluation of Algan Hemostatic Agent's effect in a Rat Experimental Spleen Injury Model

Abstract

Uncontrolled hemorrhage may result from injuries to the parenchym and splenic capsule. Hemostatic material applications are among the methods used to prevent spleen parenchymal hemorrhage. Algan Hemostatic Agent (AHA) is a standardized mixture of six distinct herbs that are capable of hemostasis, either individually or in combination. Aim of this study was to investigate efficiency of AHA in bleeding control in experimental spleen injury model, and to evaluate its histopathological effects and IL-1β, TNF-α, and Bax expressions in tissue. Twenty-four Wistar albino female rats, aged 10-12 weeks, were randomly separated into three groups (n=8); control, AHA-liquid, and AHA-powder. After surgery physiological saline, liquid and powder were applied to the injured area for twenty seconds. On the tenth postoperative day all rats’ spleens were removed for histopathological and immunohistochemical analysis. The AHA-liquid group demonstrated more efficacy in controlling hemorrhage than the AHA powder group after both the initial and subsequent applications. Parenchyma of the spleen was intact, and a thin capsule was detected in the liquid group. In the powder group, thick granulation tissue was observed along with acute lymphocyte and neutrophil infiltration. Expressions of IL-1 β and TNF-α were mild in control and AHA-liquid groups and intense in AHA-powder groups. Similar Bax protein expression was detected in all groups. Current study demonstrated that liquid form of AHA was more effective in reducing local bleeding and inflammation in spleen tissue. Therefore, liquid form could be preferred in animal experiments and clinics as a rapid, safe, and effective agent for organ injury.

Keywords

• Algan Hemostatic Agent
• splenectomy
• histopathology
• immunohistochemistry
• bleeding
• rat

References

1. 1. Sharifi Y, Nikravan Mofard M, Jamsahar M, Nasiri M, Safari M. Knowledge, Attitude, and Practice of Emergency Medical Services Staff in Bleeding Control of Trauma Patients; a Cross sectional Study. Arch Acad Emerg Med. 2020; 8(1): e11.
2. 2. Allison HA. Hemorrhage Control: Lessons Learned From the Battlefield Use of Hemostatic Agents That Can Be Applied in a Hospital Setting. Critical Care Nursing Quarterly. 2019; 42(2): 165-72.
3. 3. Pereira BM, Bortoto JB, Fraga GP. Topical hemostatic agents in surgery: review and prospects. Rev Col Bras Cir. 2018; 45(5): e1900.
4. 4. Khoshmohabat H, Paydar S, Kazemi HM, Dalfardi B. Overview of Agents Used for Emergency Hemostasis. Trauma Mon. 2016; 21(1): e26023.
5. 5. Saverio D, Moore E, Tugnoli G, et al. Nonoperative management of liver and spleen traumatic injuries: a giant with clay feet. World Journal of Emergency Surgery. 2012; 7: 3.
6. 6. Zahir M, Akbar H, Akhtar R, et al. Comparison of conventional methods with commercially available topical hemostat surgical snow (oxidized cellulose) for achieving hemostasis in canine model of partial splenectomy. Pol J Vet Sci. 2021; 24(2): 281-86.
7. 7. Beuran M, Gheju I, Venter MD, Marian RC, Smarandache R. Non-operative management of splenic trauma. J Med Life. 2012; 5(1): 47-58.
8. 8. Kuzu A, Aydıntuğ S, Karayalçın K, Köksoy C, Yerdel MA, Eraslan S. Use of autologous fibrin glue in the treatment of splenic trauma: an experimental study. J R Coll Surg Edinb. 1992; 37(3): 162-4.

9. 9. Allotey JK, King AH, Kumins NH, et al. Systematic review of hemostatic agents used in vascular surgery. J Vasc Surg. 2021; 73(6): 2189-97.
10. 10. Nenezic D, Ayguasanosa J, Menyhei G, et al. A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg. 2019; 70(5): 1642-51.
11. 11. Schwartz M, Madariaga J, Hirose R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg. 2004; 139(11): 1148-54.
12. 12. Radwan-Pragłowska J, Piątkowski M, Deineka V, et al. Chitosan-Based Bioactive Hemostatic Agents with Antibacterial Properties-Synthesis and Characterization. Molecules. 2019 ;24(14): 2629.
13. 13. Huang L, Liu GL, Kaye AD, Liu H. Advances in Topical Hemostatic Agent Therapies: A Comprehensive Update. Adv Ther. 2020; 37(10): 4132-48.
14. 14. Hori H, Hattori S, Inouye S, et al. Analysis of the major epitope of the alpha2 chain of bovine type I collagen in children with bovine gelatin allergy. J Allergy Clin Immunol. 2002; 110(4): 652-57.
15. 15. Gedar Totuk ÖM, Güzel ŞE, Ekici H, et al. Effects of Algan Hemostatic Agent on bleeding time in a rat tail hemorrhage model. Ulus Travma Acil Cerrahi Derg. 2020; 26(6): 853-58.
16. 16. Midi A, Kumandaş A, Ekici H, Kılıç Y, Özgöçmen R. Effectiveness of Algan Hemostatic Agent in Bleeding Control: An Experimental Kidney Incision Model. The Medical Bulletin of Haseki. 2021; 59: 43-7.
17. 17. Sener D, Kocak M, Saracoglu R, Deveci U, Karadağ M. Histopathological effects of Algan hemostatic agent (AHA) in liver injury model in rats. Hepatol Forum. 2022; 3(1): 16 -20.
18. 18. Midi A, Ekici H, Kumandaş A, et al. Investigation of the effectiveness of Algan Hemostatic Agent in bleeding control using an experimental partial splenectomy model in rats. Marmara Medical Journal. 2019; 32: 27-32.
19. 19. Akçora DS, Şanlı ZK, Hossa AA, Türet DM, Şeker U. Hemostatic Efficacy of Algan Hemostatic Agent in Renal Vein Incision Model in Rats. Journal of Harran University Medical Faculty. 2023; 20(1): 13-8.
20. 20. Aksoy H, Sener A, Akakın D, et al. The effect of Algan Hemostatic Agent (AHA) on Wound Healing. Clinical and Experimental Health Sciences. 2020; 10: 279-84.
21. 21. Bothin C, Okada M, Midtvedt T, Perbeck L. The intestinal flora influences adhesion formation around surgical anastomosis. Br J Surg. 2001; 88(1): 143-5.
22. 22. Seker U, Kaya S, Kandemir SI, Sener D, Demirel OU, Nergiz Y. Effects of black cumin seed oil on oxidative stress and expression of membrane-cytoskeleton linker proteins, radixin, and moesin in streptozotocin-induced diabetic rat liver. Hepatol Forum. 2022; 3(1): 21-6.
23. 23. Xing D, Li P, Yang Y, Yao J. Retrospective assessment of the clinical efficacy of laporoscopic partial splenectomy. Exp Ther Med. 2023; 25(5): 210.
24. 24. Schwaitzberg SD, Chan MW, Cole DJ, et al. Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage. J Trauma. 2004; 57(1): 29-32.
25. 25. Chan MW, Schwaitzberg SD, Demcheva M, Vournakis J, Finkielsztein S, Connolly RJ. Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage. J Trauma. 2000; 48(3): 454-58.
26. 26. Holcomb JB, McClain JM, Pusateri AE, et al. Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats. J Trauma. 2000; 49(2): 246-50.
27. 27. Midi A, Özyurek HE, Karahan S, et al. Investigation of Efficacy of the Plant Based Algan Hemostatic Agent, In Hepatectomy Bleeding Model In Rats. EJMI. 2018; 2(4): 195-201.
28. 28. Yavuz E, Kalaycı MU, Kesici S, Kesici U, Ozkara S, Yalcın O. Efficacy of ankaferd blood stopper in bleeding control in experimental partial splenectomy model. Kafkas Univ Vet Fak Derg. 2012; 18(5): 753-58.
29. 29. Taşkın AK, Yaşar M, Özaydın I, et al. The hemostatic effect of calcium alginate in experimental splenic injury model. Ulus Travma Acil Cerrahi Derg. 2013; 19(3): 195-99.
30. 30. Aarons CB, Cohen PA, Gower A, et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg. 2007; 245(2): 176-84.
31. 31. Bae JS, Ahn SJ, Yim H, Jang KH, Jin HK. Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model. Ann Surg. 2005; 241(3): 534-40.
32. 32. Galili Y, Ben-Abraham R, Rabau M, Klausner J, Kluger Y. Reduction of surgery-induced peritoneal adhesions by methylene blue. Am J Surg. 1998; 175(1): 30-2.
33. 33. Takagi T, Tsujimoto H, Torii H, Ozamoto Y, Hagiwara A. Two-layer sheet of gelatin: A new topical hemostatic agent. Asian J Surg. 2018; 41(2): 124-30.
34. 34. Beyazit F, Buyuk B. An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation. Rev Assoc Med Bras. 2019; 65(2): 183-90.